{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=3",
    "query": {
      "intervention": "Solution Vehicle",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 455,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Solution+Vehicle&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T03:56:21.293Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04097730",
      "title": "Steroids and Cross-linking for Ulcer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratitis Bacterial"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Difluprednate Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Riboflavin Ophthalmic",
          "type": "DRUG"
        },
        {
          "name": "Topical Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Thomas M. Lietman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 280,
      "start_date": "2020-09-24",
      "completion_date": "2024-09-18",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Miami, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04097730"
    },
    {
      "nct_id": "NCT03124407",
      "title": "Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Capsaicin Topical Solution",
          "type": "DRUG"
        },
        {
          "name": "Drug product vehicle",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Propella Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2016-07",
      "completion_date": "2016-10",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 3,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03124407"
    },
    {
      "nct_id": "NCT02965781",
      "title": "Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Herpes Labialis",
        "Cold Sore"
      ],
      "interventions": [
        {
          "name": "SADBE",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Squarex, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 139,
      "start_date": "2016-12",
      "completion_date": "2018-12-20",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 5,
      "location_summary": "Redwood City, California • Doral, Florida • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02965781"
    },
    {
      "nct_id": "NCT03404115",
      "title": "A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Syndrome"
      ],
      "interventions": [
        {
          "name": "Reproxalap Ophthalmic Solution (0.25%)",
          "type": "DRUG"
        },
        {
          "name": "Reproxalap Ophthalmic Solution (0.1%)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2018-01-02",
      "completion_date": "2018-07-11",
      "has_results": true,
      "last_update_posted_date": "2025-02-06",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 6,
      "location_summary": "Waterbury, Connecticut • Indianapolis, Indiana • Lewiston, Maine + 3 more",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lewiston",
          "state": "Maine"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Raynham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03404115"
    },
    {
      "nct_id": "NCT04556838",
      "title": "Study of VVN001 Ophthalmic Solution in Dry Eye Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "VVN001 Ophthalmic Solution 1%",
          "type": "DRUG"
        },
        {
          "name": "VVN001 Ophthalmic Solution 5%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VivaVision Biotech, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2020-12-03",
      "completion_date": "2021-12-01",
      "has_results": true,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04556838"
    },
    {
      "nct_id": "NCT06244316",
      "title": "A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "rhNGF 5 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "rhNGF 10 μg/mL",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (Placebo solution)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dompé Farmaceutici S.p.A",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 317,
      "start_date": "2024-01-22",
      "completion_date": "2024-12-04",
      "has_results": true,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 10,
      "location_summary": "Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06244316"
    },
    {
      "nct_id": "NCT05134974",
      "title": "Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mydriasis",
        "Dilation"
      ],
      "interventions": [
        {
          "name": "Phentolamine Ophthalmic Solution 0.75%",
          "type": "DRUG"
        },
        {
          "name": "Phentolamine Ophthalmic Solution Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Opus Genetics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 368,
      "start_date": "2021-11-18",
      "completion_date": "2022-03-29",
      "has_results": true,
      "last_update_posted_date": "2023-08-29",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 15,
      "location_summary": "Newport Beach, California • Westminster, California • Delray Beach, Florida + 12 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Westminster",
          "state": "California"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        },
        {
          "city": "Longwood",
          "state": "Florida"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05134974"
    },
    {
      "nct_id": "NCT02653391",
      "title": "A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fuchs' Corneal Endothelial Dystrophy (FCED)"
      ],
      "interventions": [
        {
          "name": "Part A Elamipretide 1.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part B Elamipretide 3.0% Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Part A Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stealth BioTherapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2016-02",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2021-09-17",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 2,
      "location_summary": "Edgewood, Kentucky • Boston, Massachusetts",
      "locations": [
        {
          "city": "Edgewood",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02653391"
    },
    {
      "nct_id": "NCT03691649",
      "title": "A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma and Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "DE-117 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Timolol Maleate Ophthalmic Solution 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 426,
      "start_date": "2018-09-14",
      "completion_date": "2020-09-03",
      "has_results": true,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 47,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03691649"
    },
    {
      "nct_id": "NCT04983589",
      "title": "A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Presbyopia"
      ],
      "interventions": [
        {
          "name": "Pilocarpine HCl",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "40 Years to 55 Years"
      },
      "enrollment_count": 230,
      "start_date": "2021-09-02",
      "completion_date": "2022-02-11",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-10-23T03:56:21.293Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Glendale, California • Inglewood, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04983589"
    }
  ]
}